Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Greg22 who wrote (18096)	1/24/1999 6:00:00 PM
From: VLAD	Respond to of 23519

Gr&St, Last year I posted a link on this thread to Dr Christ's gene therapy article which was published in the American Journal of Physiology: Heart and Circulatory Physiology Edition. To this day it is the only published work I have seen. I don't know what the post number was and would like to post it so that any new comers here can see that this gene therapy stuff isn't just hype but does indeed have a lot of promise to treat organic vascular ED patients. If anyone can find the article please post the link. Perhaps we can start a new thread dedicated exclusively to any articles/information that develops regarding gene therapy so that all can readily look up the info and know where to contribute. Here is the abstract link: oac.hsc.uth.tmc.edu When I try to obtain the full article report I find that the web site is broken.

To: Greg22 who wrote (18096)	1/24/1999 6:12:00 PM
From: VLAD	Respond to of 23519

After some more digging I just discovered that the American journal of Physiology: Heart and Circulation Physiology can no longer be accessed electronically for free: ajpheart.physiology.org

To: Greg22 who wrote (18096)	1/24/1999 6:51:00 PM
From: DaiS	Read Replies (1) \| Respond to of 23519

Gr&St, I agree. All these crap companies with no product nor profits and massive share price do so on the basis of a dream and a wish. When they actually have a crap product to sell they will fall from the stars. If vivus only had muse now I would not be prepared to pay more than say ten years 1999 prospective earnings per share. On this basis $10 might be a fair price. Take away muse, alibra from Vivus, leave the gene therapy, change the name to GEN-ED, new management. ((Maybe we could add in possibility that the therapy might also be applied to other conditions where additional K-channels beneficial.)) Have a bit of a media splash when company launched and phase I trials.....gene therapy for ED to replace viagra, pills...blah, blah. I bet each of 30M shares would be worth more than $3. And again it would be on a dream and a prayer for we do not yet have this gene therapy for ED. I assume that at the cc we will hear something about the diabetic rats. But I am more interested in the progress of the work on assuring even distribution of the injected DNA construct. With a bit more advance in this area I think there will be the phase I trials. DaiS